EP3409273A1 — Extended release multiparticulates of ranolazine
Assigned to Sun Pharmaceutical Industries Ltd · Expires 2018-12-05 · 7y expired
What this patent protects
The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazineor a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multi…
USPTO Abstract
The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazineor a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foodsor liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulatecomposition and method of treatment of patients suffering from angina by administering said composition.
Drugs covered by this patent
- Ranexa (RANOLAZINE) · Menarini Intl
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.